Data from EMC - Curated by Toby Galbraith - Last updated 19 July 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Treatment of bleeding episodes in patients with acquired haemophilia caused by antibodies to Factor VIII.

OBIZUR is indicated in adults.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients

Visit Oral Anticoagulation Reversal


Hypogonadism

Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more

Visit Hypogonadism


Related Content

More information

Category Value
Agency product number EMEA/H/C/002792
Orphan designation No
Date First Approved 11-11-2015
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Baxalta Innovations GmbH
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions